The Clinical Study of Thymosinα1 Therapeutic Effect of Chemotherapy in Advanced Gastric Cancer

WANG Wei-min,ZHOU Yan,TANG Yue-hua,GU Xian-cheng,ZHANG Guo-qiang
DOI: https://doi.org/10.13241/j.cnki.pmb.2011.24.055
2011-01-01
Abstract:Objective: Detecting peripheral blood immune parameters in patients with gastric cancer by Flow cytometry(FCM),to evaluate the immune function in gastric cancer patients by the thymosinα1 combination chemotherapy.Methods: 70 patients with gastric cancer were randomly divided into treatment and control groups.Treatment group of 35 cases deploy thymosin α1 combination chemotherapy,35 patients in control group receive chemotherapy alone,two groups of chemotherapy schedule are identical.Thymosin α1 1.6mg every time,2 times per week,continuing 4 weeks(total 8 pin).28 days for a course,keeping on 2 courses.By FCM,Two groups were detected CD4,CD8,CD3 + CD4 +,CD3 + CD8 + in patients with peripheral blood before and after chemotherapy.Results: The level of CD4,CD8,CD3 + CD4 +,CD4/CD8 in the treatment group were higher than those before chemotherapy and the control group after chemotherapy,There were statistically significant(P <0.05).Conclusion: Thymosin α1 with chemotherapy can improve im-mune function in patients,to detect peripheral blood immune parameters by FCM provide an effective basis for clinical observation of the immune status of cancer patients.
What problem does this paper attempt to address?